LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+27.42%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$855M
AUM Growth
+$855M
(-4.3%)
Cap. Flow
+$19.6M
Cap. Flow
% of AUM
2.3%
Top 10 Holdings %
Top 10 Hldgs %
52.05%
Holding
71
New
17
Increased
11
Reduced
9
Closed
23
Top Buys
| 1 |
BioNTech
BNTX
|
$34.2M |
| 2 |
Insmed
INSM
|
$31.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
$27.3M |
| 4 |
Cytokinetics
CYTK
|
$23.5M |
| 5 |
IDEAYA Biosciences
IDYA
|
$23.1M |
Top Sells
| 1 |
Disc Medicine
IRON
|
$46.6M |
| 2 |
Celldex Therapeutics
CLDX
|
$30.6M |
| 3 |
Ionis Pharmaceuticals
IONS
|
$30M |
| 4 |
Galapagos
GLPG
|
$23M |
| 5 |
Cogent Biosciences
COGT
|
$21.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
IDEAYA Biosciences
IDYA
$2.15B
| $77.1M | 9.02% | 3,000,000 +900,000 | +43% | +$23.1M |
|
2
Janux Therapeutics
JANX
$1.37B
| $66.9M | 7.83% | 1,250,000 +250,000 | +25% | +$13.4M |
|
3
Revolution Medicines
RVMD
$7.1B
| $63.4M | 7.42% | 1,450,000 +250,000 | +21% | +$10.9M |
|
|
4
Cytokinetics
CYTK
$4.23B
| $42.3M | 4.95% | 900,000 +500,000 | +125% | +$23.5M |
|
5
Vera Therapeutics
VERA
$1.38B
| $37M | 4.33% | 875,000 +375,000 | +75% | +$15.9M |
|
|
6
BioNTech
BNTX
$24B
| $34.2M | 4% | +300,000 | New | +$34.2M |
|
7
Merus
MRUS
$4.98B
| $31.5M | 3.69% | 750,000 +175,000 | +30% | +$7.36M |
|
8
Erasca
ERAS
$445M
| $31.4M | 3.67% | 12,500,000 +1,600,000 | +15% | +$4.02M |
|
|
9
Insmed
INSM
$28.8B
| $31.1M | 3.64% | +450,000 | New | +$31.1M |
|
10
Ocular Therapeutix
OCUL
$2.12B
| $29.9M | 3.5% | 3,500,000 | – | – |
|
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $27.3M | 3.19% | +200,000 | New | +$27.3M |
|
12
Design Therapeutics
DSGN
$315M
| $26M | 3.04% | 4,217,627 | – | – |
|
13
Vaxcyte
PCVX
$4B
| $24.6M | 2.87% | 300,000 | – | – |
|
14
Akero Therapeutics
AKRO
$3.74B
| $22.3M | 2.6% | 800,000 | – | – |
|
15
Jazz Pharmaceuticals
JAZZ
$7.75B
| $21.6M | 2.52% | +175,000 | New | +$21.6M |
|
16
Structure Therapeutics
GPCR
$1.11B
| $19M | 2.22% | 700,000 -550,000 | -44% | -$14.9M |
|
17
Olema Pharmaceuticals
OLMA
$375M
| $18.7M | 2.19% | 3,208,875 | – | – |
|
|
BPMC
18
DELISTED
Blueprint Medicines
BPMC
| $17.4M | 2.04% | +200,000 | New | +$17.4M |
|
19
Travere Therapeutics
TVTX
$1.56B
| $17.4M | 2.04% | 1,000,000 -100,000 | -9% | -$1.74M |
|
20
Apellis Pharmaceuticals
APLS
$3.48B
| $16M | 1.87% | +500,000 | New | +$16M |
|
21
Soleno Therapeutics
SLNO
$3.6B
| $15.7M | 1.84% | +350,000 | New | +$15.7M |
|
22
Alkermes
ALKS
$4.78B
| $14.4M | 1.68% | +500,000 | New | +$14.4M |
|
23
Apogee Therapeutics
APGE
$2.17B
| $13.6M | 1.59% | +300,000 | New | +$13.6M |
|
24
Arvinas
ARVN
$568M
| $13.4M | 1.57% | 700,000 +300,000 | +75% | +$5.75M |
|
25
Annexon
ANNX
$226M
| $13.1M | 1.53% | 2,550,000 -50,000 | -2% | -$257K |
|